Eleonora Restuccia

Title: Eleonora Restuccia: Innovator in Fixed Dose Combinations

Introduction

Eleonora Restuccia is a prominent inventor based in Basel, Switzerland. She has made significant contributions to the field of pharmaceuticals, particularly in the development of fixed dose combinations for cancer treatment. Her innovative work has the potential to improve patient outcomes and streamline treatment protocols.

Latest Patents

Restuccia holds a patent for a fixed dose combination of pertuzumab and trastuzumab, which is administered subcutaneously to patients. This invention, titled "Pertuzumab plus trastuzumab fixed dose combination," also includes the optional use of recombinant human hyaluronidase (rHuPH20). The patent encompasses the final efficacy and safety data from the FeDeriCa clinical trial, as well as the United States Prescribing Information (USPI) and primary analysis of the PHranceSCa clinical trial.

Career Highlights

Throughout her career, Restuccia has worked with leading pharmaceutical companies, including Genentech, Inc. and Hoffmann-La Roche Inc. Her experience in these organizations has allowed her to contribute to groundbreaking research and development in the field of oncology.

Collaborations

Restuccia has collaborated with notable colleagues such as Tanja Badovinac-Crnjevic and Yu Chien Fredriksson. These partnerships have further enhanced her research and innovation efforts in the pharmaceutical industry.

Conclusion

Eleonora Restuccia is a trailblazer in the development of fixed dose combinations for cancer therapies. Her patent and collaborations reflect her commitment to advancing medical science and improving patient care.